The Oncology Institute

The Oncology Institute, Inc. provides cancer care treatment services. It offers evidence-based cancer care to patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. The company is headquartered in Cerritos, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

The Oncology Institute reports strong revenue growth amidst operational challenges

TOI's Q1 2024 performance showcased robust revenue growth driven by strategic partnerships and record prescription sales, despite challenges with drug margin compression.
Operational achievements and a healthy cash position provide a strong foundation for TOI to navigate challenges and capitalize on growth opportunities in the oncology market.
By focusing on strategic priorities outlined by CEO Daniel Virnich, TOI aims to enhance profitability, expand market presence, and lead in value-based oncology care.

The Oncology Institute reports strong Q2 growth amid margin challenges

TOI's Q2 2024 earnings call reflected strong revenue growth but challenges with margins and profitability. The company is focused on addressing margin pressures and enhancing shareholder value through strategic initiatives.

The Oncology Institute reports robust Q3 growth and strategic focus

TOI's Q3 2024 performance reflects strong revenue growth, cost management, and strategic initiatives to drive operational efficiency and compliance.
The company's strengths lie in proactive cost optimization, expanded service offerings, and a clear strategic direction towards growth and performance.
Challenges include regulatory compliance, profitability sustainability, and ongoing efforts to balance financial flexibility with quality care delivery.
Opportunities abound in stable revenue streams, strategic partnerships, and enhanced profitability through optimized cost structures and market positioning.

The Oncology Institute reports strong revenue growth and aims for profitability by Q4 2025

TOI's strong 2024 performance, with a 21% revenue increase and profitability enhancements, sets a positive foundation for future growth. The company's focus on operational improvements and market expansion aligns with its goal of achieving cash flow breakeven by Q4 2025. While challenges exist in executing plans and maintaining growth momentum, TOI's clear guidance for 2025 and proactive approach to addressing analyst inquiries demonstrate a commitment to transparency and strategic planning. Opportunities for continued growth and financial strengthening through market expansion and operational optimization position TOI for success. Navigating the evolving reimbursement landscape and effectively communicating performance metrics will be key for TOI's sustained success. The company's financial stability, highlighted by balance sheet improvements and revenue growth, reflects a resilient and forward-thinking approach to the oncology market.

The Oncology Institute reports revenue growth and operational enhancements in Q1 2025

TOI's Q1 2025 performance showed revenue growth, improved gross profit, and enhanced cost management. While challenges like EBITDA losses persist, opportunities in new markets and clinical excellence initiatives are promising. Strategic financial moves and operational improvements position TOI for future growth and competitiveness. Continued focus on profitability, innovation, and market expansion will be key for TOI's success in the oncology sector.

The Oncology Institute reports robust Q2 growth and strategic leadership changes

TOI's Q2 2025 performance showcased strong revenue growth and operational improvements. While facing an EBITDA loss, the company's strategic initiatives and leadership changes position it for future success. Opportunities in pharmacy business growth and new contracts provide avenues for revenue expansion. Guidance for the full year indicates confidence in TOI's ability to navigate challenges and drive growth.

The Oncology Institute reports strong Q3 results amidst cybersecurity challenges

TOI's Q3 2025 performance showcased strong revenue growth and progress in operational efficiency despite challenges from a cybersecurity incident. The company's resilience, expansion efforts, and proactive management approach position it well for future growth and financial stability. Addressing concerns about reserves, profitability sustainability, and growth prospects demonstrates TOI's commitment to overcoming challenges and seizing opportunities.

The Oncology Institute reports first profitable quarter, eyes strategic growth

TOI's Q4 2025 performance showcased financial resilience and strategic growth initiatives, positioning the company for continued success. While facing challenges in profitability and cash flow management, TOI's proactive approach to innovation and market expansion presents opportunities for sustainable growth. Investors should monitor TOI's execution of 2026 plans, focusing on maintaining profitability, expanding partnerships, and leveraging new growth avenues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Oncology Institute, Inc. provides cancer care treatment services. It operates through the following business segments: Dispensary, Patient Care, and Clinical Trials and Other. The company was founded in 2007 and is headquartered in Cerritos, CA.